JUNIPER PUBLISHERS-Novel Approaches in Drug Designing & Development
Functional Selective D2 Ligands for the Treatment of Schizophrenia
Authored by Xin Chen*
Functionally selective ligands (also
known as biased ligands) of dopamine D2 receptors have been considered as not
only valuable tools for dissecting the roles of D2-mediated G protein-dependent
and independent signaling pathways, but also better antipsychotic drug
candidates for neurological and psychiatric disorders including schizophrenia.
Consequently, functionally selective D2R ligands have also been increasingly
pursued by the biomedical community as promising antipsychotic therapeutics
with improved efficacy and reduced side effects compared with unbiased ligands.
This review will discuss the recent development in the discovery of functional
selective D2R ligands. Schizophrenia is a chronic and severe mental disorder
characterized by abnormal social behavior and failure to understand reality.
Clinically, the disorder manifests with a large variety of symptoms that fall
into three categories: positive, negative, and cognitive. Schizophrenia affects
about 1.1% of world wide population. Although schizophrenia is not as common as
other mental disorders such as anxiety disorder (18.1%), depression (6.9%), and
bipolar disorder (2.6%), the symptoms can be very disabling. Therefore, it is
often associated with high levels of morbidity and mortality. The average life
expectancy of people with schizophrenia is ten to twenty-five years less than
for the general population. This is the result of increased physical health
problems and a higher suicide rate (about 10%)
For More Articles in Novel
Approaches in Drug
Designing & Development Please Click on:
https://juniperpublishers.com/napdd/index.php
For More Open
Access Journals In Juniper Publishers Please Click on:
No comments:
Post a Comment